Enhanced treatment of brain tumors

November 28, 2011

Glioblastoma is regarded as the most malignant form of brain tumor. In many cases, neurosurgeons are not able to remove such tumors completely because of the risk of destroying too much brain tissue in the process. Moreover, it is often impossible to identify all the fine extensions by which the tumor spreads into surrounding healthy tissue. To at least slow down the growth of tumor cells that have remained in the head, almost all glioblastoma patients are treated by radiotherapy after surgery.

"Unfortunately, we can only delay cancerous growth in this way, but we cannot cure patients. The tumor cells, especially the cancer stem cells, are very resistant to radiation," says Prof. Dr. Dr. Peter Huber, who is head of the Clinical Cooperation Unit 'Radiation Oncology' at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

Studies conducted in recent years found that response to radiation therapy in various cancers is better when certain types of cellular growth factors are blocked at the same time. Glioblastoma cells often produce large amounts of a growth factor called TGF-β (transforming growth factor beta). High levels of TGF-β in these tumors are correlated with particularly aggressive growth and a poor prognosis. In addition, the factor seems to support the self-renewal capability of glioblastoma stem cells. "We therefore suspect that blocking TGF-β signaling pathways slows down the self-renewal of cancer stem cells and, thus, may improve radiation treatment outcomes," Peter Huber adds, explaining the background of the study now published.

In collaboration with colleagues from, among others, the Radiology Department of Heidelberg University Hospitals and a DKFZ department led by Prof. Dr. Ana Villalba, Huber's team investigated the effect of a combination of radiation treatment and a newly developed substance called LY2109761. This substance blocks the signals that are transmitted into cells by the TGF-β receptor. The investigators first studied glioblastoma cells in tissue samples taken during surgical removal of the tumors. Irradiation combined with adding the substance reduced the self-renewal capability of tumor stem cells and delayed their growth significantly better than radiation treatment alone.

The group transplanted human glioblastoma cells into the brains of mice and found that these animals, after receiving the combination therapy, survived longer than those animals treated by radiotherapy alone. Tissue studies showed that, under the combination therapy, tumors grew more slowly and less invasively and showed a lower density of newly formed blood vessels. "Paradoxically, radiation therapy can provoke aggressive growth behavior in surviving tumor cells. LY2109761 seems to prevent this fatal effect," says Huber, explaining how the drug seems to work.

Blocking of TGF-β signaling produced such promising results that researchers will now conduct a multicenter clinical trial to find out whether this mechanism may also slow down glioblastoma growth in patients more effectively than the current standard treatment. Led by Prof. Dr. Wolfgang Wick, who is head of a collaboration unit of DKFZ and the Neurology Department of Heidelberg University Hospitals, the combination therapy will be tested in Germany (Heidelberg), Spain, and the U.S.A.

Helmholtz Association of German Research Centres

---

---

	Medifocus Guidebook on: Glioblastoma by Medifocus.com Inc. (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Glioblastoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Glioblastoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Glioblastoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations...
	Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever.  A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor.  I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor.  This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years.  I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level.  I could not find, so I wrote one.  I maintained a detailed journal.  I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second...
	Glioblastoma Multiforme by James Markert (Author), Vincent T. DeVita Jr. (Author), Steven A. Rosenberg (Author), Samuel Hellman (Author) This Book Provides Basic Researchers And Clinicians With A Contemporary Review Of The Epidemiology, Diagnosis, And Treatment Of Glioblastoma Multiforme, The Most Common And Most Deadly Type Of Brain Tumor. Expert Malignant Glioma Researchers And Clinicians Provide State-Of-The-Art Chapters On Important Topics Such As Molecular Genetic Classification Of Glioblastoma, Surgical Management, Stem Cell Therapy, Chemotherapy, Angiogenesis, And More.
	Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About by Ben A. Williams (Author) Describes how to use the Internet and other sources to learn about experimental drug trials, effective forms of alternative medicine, and other breakthroughs with the potential for dramatically improving the odds of successful treatment.
	What You Need to Know About Glioblastoma Cancer - It's Your Life, Live It! by Cancer Group Institute As an Oncology Nurse. I had only one protocol in mind while writing this 195 page book. That was to show you the most successful cancer treatments available today for Glioblastoma Cancer. To that end, you won't find a better warrior in the war on cancer than reading this book. We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional Cancer Center, Instituto Oncologia Moderna, Puerto Rico plus many others. It is critical to get prompt diagnosis and proper treatment for glioblastoma cancer, this can literally make the difference between life and death. Understanding your options will give you...
	Glioblastoma:: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies by Swapan K. Ray (Editor) Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for...
	Tumors of the Central Nervous System, Volume 1: Gliomas: Glioblastoma (Part 1) by M. A. Hayat (Editor) The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers is included. The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of cancer stem cells in the initiation, progression, and persistence of malignant gliomas is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed.
	Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional...
	Tumors of the Central Nervous System, Volume 2: Gliomas: Glioblastoma (Part 2) by M.A. Hayat (Editor) Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients...
	A Statistic of One: My Walk With Glioblastoma Multiforme by Stephen Hatrak (Author) A Statistic of One: My Walk with Glioblastoma Multiforme traces Stephen Hatrak's life from his diagnosis of glioblastoma multiforme, the deadliest of malignant brain tumors, to the present. He chronicles the trials and tribulations he faced and the losses he suffered along his journey. Faith and inner strength are formidable allies in overcoming any tragedy in one's life, and they played vital roles in his struggle. He was told from the start that the he might have twelve months to live; even so, he defi ed the odds and, six years later, is telling his own story. Despite the dire statistics associated with a diagnosis of glioblastoma, there are several stories of long-term survival; these stories gave him hope that this cancer could be tamed. To overcome this challenge in his life, he had...